Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Alexion Pharm Inc (ALXN)

Alexion Pharm Inc (ALXN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 39,935,924
  • Shares Outstanding, K 221,019
  • Annual Sales, $ 6,070 M
  • Annual Income, $ 603,400 K
  • 60-Month Beta 1.28
  • Price/Sales 6.55
  • Price/Cash Flow 7.89
  • Price/Book 3.20
Trade ALXN with:

Options Overview

Details
  • Implied Volatility 18.17%
  • Historical Volatility 9.69%
  • IV Percentile 12%
  • IV Rank 8.52%
  • IV High 57.79% on 09/04/20
  • IV Low 14.48% on 05/24/21
  • Put/Call Vol Ratio 0.63
  • Today's Volume 438
  • Volume Avg (30-Day) 659
  • Put/Call OI Ratio 2.22
  • Today's Open Interest 31,076
  • Open Int (30-Day) 27,739

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate 3.15
  • Number of Estimates 5
  • High Estimate 3.57
  • Low Estimate 2.89
  • Prior Year 2.87
  • Growth Rate Est. (year over year) +9.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
174.61 +3.48%
on 05/19/21
183.05 -1.29%
on 06/16/21
+5.82 (+3.33%)
since 05/18/21
3-Month
150.35 +20.18%
on 03/19/21
183.05 -1.29%
on 06/16/21
+29.42 (+19.45%)
since 03/18/21
52-Week
99.91 +80.85%
on 08/21/20
183.05 -1.29%
on 06/16/21
+64.37 (+55.34%)
since 06/18/20

Most Recent Stories

More News
Alexion Wins Treasury Award for Technology Transformation, Using ICD

/PRNewswire/ -- Boston-based Alexion Pharmaceuticals, Inc. was highly commended for "Harnessing the Power of Technology" in 's Adam Smith Awards last week, using ICD, an independent portal provider of...

ALXN : 180.69 (+0.40%)
Caelum and Alexion Present Additional Phase 2 Data Reinforcing Safety and Tolerability of CAEL-101 in AL Amyloidosis at the European Hematology Association Congress 2021

Caelum Biosciences and Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced new Phase 2 safety and tolerability data for CAEL-101, a potentially first-in-class amyloid fibril targeted therapy, in...

ALXN : 180.69 (+0.40%)
FBIO : 3.50 (-2.78%)
Biotech Stock Roundup: BIIB's Drug Approval, ALXN Drug Label Expansion & More

The biotech sector was in focus last week with regulatory updates from Biogen (BIIB) and bluebird (BLUE), among others.

BIIB : 388.44 (+1.28%)
JNJ : 161.98 (-1.96%)
ALXN : 180.69 (+0.40%)
INCY : 83.96 (+1.00%)
BLUE : 33.15 (+0.52%)
ARGX : 318.16 (+1.03%)
Enzymes Global Market Report 2021: COVID 19 Growth And Change to 2030

Reportlinker.com announces the release of the report "Enzymes Global Market Report 2021: COVID 19 Growth And Change to 2030" - https://www.reportlinker.com/p06090632/?utm_source=GNW

ABBV : 113.12 (-1.55%)
ALXN : 180.69 (+0.40%)
AGN : 193.02 (+0.02%)
HZNP : 94.61 (+2.68%)
PFE : 38.81 (-1.70%)
Alexion's (ALXN) PNH Drug Ultomiris Gets FDA Nod for Kids

The FDA approves Alexion's (ALXN) Ultomiris for the treatment of PNH in children of one month of age and older as well as adolescents.

ALXN : 180.69 (+0.40%)
RGEN : 197.34 (-1.15%)
TECH : 431.90 (-2.99%)
KMDA : 5.74 (-0.69%)
Alexion Announces FDA Approval of ULTOMIRIS(R) (ravulizumab-cwvz) for Children and Adolescents with Paroxysmal Nocturnal Hemoglobinuria (PNH)

--- Approval based on interim results from Phase 3 study showing ULTOMIRIS demonstrated complete terminal complement inhibition through 26 weeks -

ALXN : 180.69 (+0.40%)
Immunovant (IMVT) Reports Narrower-Than-Expected Loss in Q4

Immunovant's (IMVT) earnings beat estimates in fourth-quarter fiscal 2021. Focus remains on lead pipeline candidate IMVT-1401. Stock falls.

JNJ : 161.98 (-1.96%)
ALXN : 180.69 (+0.40%)
RGEN : 197.34 (-1.15%)
IMVT : 11.23 (+0.81%)
Apellis' (APLS) Empaveli Succeeds in Treatment-Naive PNH Study

Apellis' (APLS) recently approved drug, Empaveli, demonstrates superiority in hemoglobin stabilization and reduction in LDH level in treatment-naive PNH patients.

ALXN : 180.69 (+0.40%)
ALNY : 176.89 (+2.69%)
AKTX : 1.7700 (-1.67%)
APLS : 60.11 (+0.52%)
American Kidney Fund Expands 2021 Class of Corporate Members Committed to Fighting Kidney Disease

--News Direct--

ALXN : 180.69 (+0.40%)
AMGN : 238.68 (-0.86%)
APLS : 60.11 (+0.52%)
AUPH : 13.00 (+2.85%)
DRNA : 36.18 (+1.12%)
OMER : 15.06 (+0.60%)
OPK : 3.70 (-3.65%)
DGX : 127.50 (-0.46%)
VRTX : 187.85 (-0.27%)
Apellis (APLS) Gets a Boost With FDA Approval of PNH Drug

Approval of Apellis' (APLS) Empaveli for the treatment of paroxysmal nocturnal hemoglobinuria in the United States lends a significant boost to the company's growth prospects.

ALXN : 180.69 (+0.40%)
ALNY : 176.89 (+2.69%)
AKTX : 1.7700 (-1.67%)
APLS : 60.11 (+0.52%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Alexion Pharmaceuticals, Inc. is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the innovation, development and commercialization of life-changing therapies. Alexion is the global leader in complement inhibition and has developed and commercializes...

See More

Key Turning Points

3rd Resistance Point 185.36
2nd Resistance Point 183.55
1st Resistance Point 182.12
Last Price 180.69
1st Support Level 178.88
2nd Support Level 177.07
3rd Support Level 175.64

See More

52-Week High 183.05
Last Price 180.69
Fibonacci 61.8% 151.29
Fibonacci 50% 141.48
Fibonacci 38.2% 131.67
52-Week Low 99.91

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar